Who we are

There is now more research than ever into the benefits and risks of psychedelics—from traditional psychedelics such psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, to a countless and growing number of related natural and proprietary molecules. There are hundreds of new psychedelic companies, from ketamine clinics and psychedelic retreats to pharmaceutical companies and integration services.

After decades of stigma and misunderstanding, psychedelics are here to stay. Ketamine was approved by the FDA in 2019 for the treatment of major depression (Johnson & Johnson). FDA approval is also expected for MDMA-assisted psychotherapy for PTSD and psilocybin-assisted psychotherapy for treatment-resistant depression. New legislative initiatives increasing research on and access to psychedelics are regularly being introduced.

The vast new field of psychedelic science and therapy, together with the ancillary services necessary for their safe and effective availability—treatment, integration, public and professional education, community support, research and clinical trials, retreats, and so much more—needs to expand with integrity as it grows to achieve its potential to heal minds and transform culture.

As you enter the legal psychedelic space, what will your impact be?

Much like the field of medical marijuana, psychedelics are breaking through into mainstream culture as therapeutic, scientific, and spiritual tools. As shown by the explosion of investor and philanthropic support of psychedelic research and therapy, the question is not if psychedelics will be incorporated into our legal, medical, and economic systems, but how.

For new psychedelic companies and for established brands wanting to keep up with shifts in public culture, the challenge is twofold: (1) to establish and maintain trust with donors, investors, and consumers who already recognize the potential of psychedelics; and (2) to remain accessible to those who remain (rightly after decades of misinformation) skeptical.

The current revolution in wellness and mental health is positioning psychedelics to be the first new approach to Western healthcare in decades. They’re bringing with them an entire new psychedelic industry. How can companies communicate about psychedelics in a way that reduces stigma, enhances trust, and remains in alignment with ethical values?

Integration Communications is committed to helping purpose-driven companies of all kinds expand their audience and enhance their brand with clarity, efficiency, and accountability as they work to bring psychedelics into our society.

Psychedelics are not a magic bullet—they must be used carefully, with intention, preparation, and ideally in community. In the same way, how you educate your audiences about psychedelics will affect not just their trust in your brand, but also what role psychedelics will play in their lives.

Let’s work together to make psychedelics legally and safely available to those who need them—with wisdom, integrity, and love.